AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21497319 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week supervised hip flexor stretching program
Number of subjects: 74
Study 19850207 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg daily for 6 months, increased to 50 mg daily from 6 to 12 months
Number of subjects: 44
Study 19850207 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 44
Study 17438512 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose local vaginal estrogen therapy
Number of subjects: 0
Study 15197196 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Number of subjects: 184
Study 15197196 — intervention group
Group type: COMPARATOR
Intervention: No PET
Number of subjects: 184
Study 12374247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bisphosphonates
Number of subjects: 0
Study 12374247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9825751 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg triple helical collagen type II
Number of subjects: 92
Study 9825751 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 92
Study 7813220 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dose of doxycycline
Number of subjects: 447
Study 7813220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study 2805141 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15
Study 1209742 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ampicillin (0.5-1 g into the wound before closure)
Number of subjects: 420
Study 1209742 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ampicillin)
Number of subjects: 420
Study 7352522 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration
Number of subjects: 32
Study 7352522 — intervention group
Group type: COMPARATOR
Intervention: Room air administration
Number of subjects: 32
Study 30145738 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart After-Care (smartphone application and pedometer)
Number of subjects: 356
Study 30145738 — intervention group
Group type: COMPARATOR
Intervention: Exercise education only
Number of subjects: 356
Study 28424185 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.9 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) per day for 6 months
Number of subjects: 21
Study 28424185 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4.2 g oleate per day for 6 months)
Number of subjects: 21
Study 25635359 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade reaming
Number of subjects: 94
Study 25635359 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde reaming
Number of subjects: 94
Study 25635359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 94
Study 24095609 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane + Ovarian Function Suppression (OFS)
Number of subjects: 5738
Study 24095609 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen + Ovarian Function Suppression (OFS)
Number of subjects: 5738
Study 24095609 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 5738
Study 21883635 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural sedation with etomidate as the sole agent
Number of subjects: 42
Study 21883635 — intervention group
Group type: COMPARATOR
Intervention: US-guided interscalene nerve block
Number of subjects: 42
Study 19217008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling of the lower second molar (L2M) root surface
Number of subjects: 43
Study 19217008 — intervention group
Group type: COMPARATOR
Intervention: Manual scaling and root planing
Number of subjects: 43
Study 17582705 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled HIV/HCV prevention trial
Number of subjects: 3285
Study 17582705 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessments
Number of subjects: 3285
Study 17582705 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual factors
Number of subjects: 3285
Study 14962146 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education of nurses and nursing home residents and provision of free hip protectors
Number of subjects: 511
Study 14962146 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 511
Study 14962146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group predictors: use of walking aid
Number of subjects: 511
Study 14962146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group predictors: no urinary incontinence
Number of subjects: 511
Study 14962146 — intervention group
Group type: COMPARATOR
Intervention: Usual care predictors: nursing staff per 10 residents
Number of subjects: 511
Study 14962146 — intervention group
Group type: COMPARATOR
Intervention: Usual care predictors: high degree of disablement
Number of subjects: 511
Study 14962146 — intervention group
Group type: COMPARATOR
Intervention: Usual care predictors: strong fear of falling
Number of subjects: 511
Study 14962146 — intervention group
Group type: COMPARATOR
Intervention: Nursing home cluster
Number of subjects: 511
Study 12078790 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous priming
Number of subjects: 104
Study 12078790 — intervention group
Group type: COMPARATOR
Intervention: Control (no autologous priming)
Number of subjects: 104
Study 9445321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebselen (150 mg BID for 2 weeks)
Number of subjects: 302
Study 9445321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 7614505 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril (CLZ) 1‐2.5 mg once daily (n = 221)
Number of subjects: 443
Study 7614505 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril (CPT) 25‐50 mg three times daily (n = 108)
Number of subjects: 443
Study 7614505 — intervention group
Group type: COMPARATOR
Intervention: placebo (PLA) (n = 114)
Number of subjects: 443
Study 7614505 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril (CLZ)
Number of subjects: 443
Study 7614505 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril (CPT)
Number of subjects: 443
Study 2515753 — intervention group
Group type: EXPERIMENTAL
Intervention: Once‐daily lithium carbonate (Priadal)
Number of subjects: 25
Study 2515753 — intervention group
Group type: COMPARATOR
Intervention: Twice‐daily lithium citrate (Litarex)
Number of subjects: 25
Study 983179 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP (Rifampicin)
Number of subjects: 220
Study 983179 — intervention group
Group type: COMPARATOR
Intervention: EMB (Ethambutol)
Number of subjects: 220
Study 983179 — intervention group
Group type: EXPERIMENTAL
Intervention: EMB added to chemotherapy regimen
Number of subjects: 220
Study 983179 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP added to EMB regimen
Number of subjects: 220
Study 983179 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP (Rifampicin) in 220 chronic patients
Number of subjects: 220
Study 983179 — intervention group
Group type: EXPERIMENTAL
Intervention: EMB and another combination in 54 new cases
Number of subjects: 220
Study 983179 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP added to treatment in 20 new cases
Number of subjects: 220
Study 983179 — intervention group
Group type: COMPARATOR
Intervention: RMP vs EMB
Number of subjects: 220
Study 30727996 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated mental health care program (intervention group)
Number of subjects: 349
Study 30727996 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 349
Study 29311704 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinkeliba (Combretum micranthum) 190 mg × 2/day
Number of subjects: 125
Study 29311704 — intervention group
Group type: EXPERIMENTAL
Intervention: Bissap (Hibiscus sabdariffa) 320 mg × 2/day
Number of subjects: 125
Study 29311704 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 5 mg/day
Number of subjects: 125
Study 26356750 — intervention group
Group type: EXPERIMENTAL
Intervention: Keraring implantation
Number of subjects: 29
Study 26356750 — intervention group
Group type: COMPARATOR
Intervention: Keraring insertion followed by TE‐CXL 1 month later
Number of subjects: 29
Study 23418955 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (IHG) for 10 weeks
Number of subjects: 24
Study 23418955 — intervention group
Group type: COMPARATOR
Intervention: Control group for 10 weeks
Number of subjects: 24
Study 23418955 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training systolic BP reactivity to SST and IHGT
Number of subjects: 24
Study 25551914 — intervention group
Group type: EXPERIMENTAL
Intervention: New protocol of arterial puncture with fine needle (paf)
Number of subjects: 0
Study 25551914 — intervention group
Group type: COMPARATOR
Intervention: Traditional arterial puncture methods
Number of subjects: 0
Study 19967620 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring (n = 46)
Number of subjects: 90
Study 19967620 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 44)
Number of subjects: 90
Study 16965419 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI
Number of subjects: 16
Study 16965419 — intervention group
Group type: EXPERIMENTAL
Intervention: LS-PGA
Number of subjects: 16
Study 16965419 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA
Number of subjects: 16
Study 15181054 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg/d)
Number of subjects: 82
Study 15181054 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1000 mg/d)
Number of subjects: 82
Study 15181054 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 82
Study 12085979 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone therapy
Number of subjects: 0
Study 12085979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9850359 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP 400 micrograms day-1 (delivered as four actuations of 50 micrograms twice daily)
Number of subjects: 256
Study 9850359 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP 400 micrograms day-1 (delivered as two actuations of 100 micrograms twice daily)
Number of subjects: 256
Study 9850359 — intervention group
Group type: COMPARATOR
Intervention: HFA-placebo
Number of subjects: 256
Study 9850359 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP (both dosing regimens)
Number of subjects: 256
Study 7866911 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet (150 mg calcium and 1600 mg phosphorus daily)
Number of subjects: 30
Study 7866911 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum intact parathyroid hormone (PTH) concentration
Number of subjects: 30
Study 2670633 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base (1 g/day)
Number of subjects: 1244
Study 2670633 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (2 g/day)
Number of subjects: 1244
Study 773506 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (75‐225 mg/day)
Number of subjects: 60
Study 773506 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol (1‐5‐4‐5 mg/day)
Number of subjects: 60
Study 773506 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study 31677259 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumor resection
Number of subjects: 2694
Study 29153759 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledgeable Together (higher dyad knowledge, less incongruence; N = 85, 75%)
Number of subjects: 114
Study 29153759 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge Gap (lower dyad knowledge, greater incongruence; N = 29, 25%)
Number of subjects: 114
Study 27775503 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term storage group (mean storage duration 13.0 days)
Number of subjects: 20858
Study 27775503 — intervention group
Group type: COMPARATOR
Intervention: Long-term storage group (mean storage duration 23.6 days)
Number of subjects: 20858
Study 27775503 — intervention group
Group type: EXPERIMENTAL
Intervention: Any blood type analysis (short-term storage)
Number of subjects: 20858
Study 27775503 — intervention group
Group type: COMPARATOR
Intervention: Any blood type analysis (long-term storage)
Number of subjects: 20858
Study 24178969 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitization therapy
Number of subjects: 1799
Study 24178969 — intervention group
Group type: COMPARATOR
Intervention: Insulin-provision therapy
Number of subjects: 1799
Study 22220945 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg DMT
Number of subjects: 51
Study 22220945 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 51
Study 20171326 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical rumination
Number of subjects: 77
Study 20171326 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 77
Study 17378781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive stellate ganglion block (SGB) using 10 ml of ropivacaine
Number of subjects: 100
Study 17378781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SGB)
Number of subjects: 100
Study 17378781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive stellate ganglion block (SGB)
Number of subjects: 100
Study 16323385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation combined with AChE‐I (rivastigmine) treatment
Number of subjects: 13
Study 16323385 — intervention group
Group type: COMPARATOR
Intervention: AChE‐I only (control group)
Number of subjects: 13
Study 12006327 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 20 mg daily
Number of subjects: 182
Study 12006327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 2.5 mg daily
Number of subjects: 182
Study 12006327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 5 mg daily
Number of subjects: 182
Study 12006327 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (all doses)
Number of subjects: 182
Study 12006327 — intervention group
Group type: COMPARATOR
Intervention: Ibandronate (all doses)
Number of subjects: 182
Study 10049274 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (100, 300, 600, 900, and 1,200 mg)
Number of subjects: 18
Study 10049274 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (300 mg)
Number of subjects: 18
Study 10049274 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (various doses)
Number of subjects: 18
Study 10049274 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 18
Study 10049274 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (caplet formulation)
Number of subjects: 18
Study 10049274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7577484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 41
Study 7577484 — intervention group
Group type: COMPARATOR
Intervention: Clodronate 1500 mg
Number of subjects: 41
Study 1971645 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (C)
Number of subjects: 0
Study 1971645 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime and Gentamicin (C + G)
Number of subjects: 0
Study 1971645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime and Teicoplanin (C + T)
Number of subjects: 0
Study 1971645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime, Gentamicin, and Teicoplanin (C + G + T)
Number of subjects: 0
Study 6784594 — intervention group
Group type: EXPERIMENTAL
Intervention: Mr. 1268 (M1)
Number of subjects: 9
Study 6784594 — intervention group
Group type: EXPERIMENTAL
Intervention: pentazocine (M2)
Number of subjects: 9
Study 6784594 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol (M3)
Number of subjects: 9
Study 6784594 — intervention group
Group type: EXPERIMENTAL
Intervention: Mr. 1353 (M4)
Number of subjects: 9
Study 31104285 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐tDCS
Number of subjects: 42
Study 31104285 — intervention group
Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 42
Study 28160670 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive CT scan of the abdomen/pelvis
Number of subjects: 854
Study 28160670 — intervention group
Group type: COMPARATOR
Intervention: Limited screening strategy
Number of subjects: 854
Study 25649637 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrafilcon A (Dk, 140)
Number of subjects: 29
Study 25649637 — intervention group
Group type: EXPERIMENTAL
Intervention: galyfilcon A (Dk, 60)
Number of subjects: 29
Study 25649637 — intervention group
Group type: EXPERIMENTAL
Intervention: +6.00 D power lenses (averaged across lens materials)
Number of subjects: 29
Study 25649637 — intervention group
Group type: EXPERIMENTAL
Intervention: -10.00 D and -3.00 D lenses
Number of subjects: 29
Study 25649637 — intervention group
Group type: COMPARATOR
Intervention: Control (no lens)
Number of subjects: 29
Study 24634622 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) therapy for 6 months
Number of subjects: 22
Study 24634622 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) therapy
Number of subjects: 22
Study 24634622 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 subjects)
Number of subjects: 22
Study 21952002 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 30 minutes of brisk walking daily for 3 weeks
Number of subjects: 33
Study 21952002 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 33
Study 19651266 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized exercise program for 4 weeks
Number of subjects: 42
Study 19651266 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 42
Study 17241844 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal placebo gel
Number of subjects: 30
Study 17241844 — intervention group
Group type: COMPARATOR
Intervention: PSS placebo gel
Number of subjects: 30
Study 15962898 — intervention group
Group type: COMPARATOR
Intervention: ORS/WHO standard treatment
Number of subjects: 101
Study 15962898 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS/plantain solution (50 g of precooked plantain flour instead of glucose)
Number of subjects: 101
Study 15962898 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS/plantain solution
Number of subjects: 101
Study 12060421 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% PHMB mouthrinse (A)
Number of subjects: 16
Study 12060421 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine rinse (C)
Number of subjects: 16
Study 12060421 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (C)
Number of subjects: 16
Study 12060421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (B)
Number of subjects: 16
Study 12060421 — intervention group
Group type: COMPARATOR
Intervention: Listerine (D)
Number of subjects: 16
Study 9796961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cremophor 30 ml/m2
Number of subjects: 10
Study 9796961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cremophor 45 ml/m2 with 35 mg/m2 doxorubicin
Number of subjects: 10
Study 9796961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cremophor 60 ml/m2
Number of subjects: 10
Study 9796961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cremophor 45 ml/m2 and 60 ml/m2
Number of subjects: 10
Study 7899064 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined concurrent bronchial artery infusion (BAI) of CDDP (50 mg) and unevenly fractionated radiotherapy
Number of subjects: 55
Study 7899064 — intervention group
Group type: COMPARATOR
Intervention: Evenly fractionated irradiation (radiation group)
Number of subjects: 55
Study 1298056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube (NGT)
Number of subjects: 90
Study 1298056 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 90
Study 1298056 — intervention group
Group type: EXPERIMENTAL
Intervention: Convenience of care (NGT)
Number of subjects: 90
Study 1298056 — intervention group
Group type: COMPARATOR
Intervention: Convenience of care (PEG)
Number of subjects: 90
Study 1298056 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction (NGT)
Number of subjects: 90
Study 1298056 — intervention group
Group type: COMPARATOR
Intervention: Patient satisfaction (PEG)
Number of subjects: 90
Study 6150716 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (3 X 200 mg/die)
Number of subjects: 10
Study 6150716 — intervention group
Group type: EXPERIMENTAL
Intervention: somatostatin infusion
Number of subjects: 10
Study 30814568 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25OHD levels (measured by genetic variants)
Number of subjects: 327478
Study 30814568 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual 25OHD-reducing genetic variants
Number of subjects: 327478
Study 30814568 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 327478
Study 29609921 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated laughter
Number of subjects: 72
Study 29609921 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous laughter
Number of subjects: 72
Study 29609921 — intervention group
Group type: COMPARATOR
Intervention: Control (non-humorous documentary)
Number of subjects: 72
Study 26705681 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (40 mg/m², 7 doses)
Number of subjects: 109
Study 26705681 — intervention group
Group type: COMPARATOR
Intervention: Triweekly cisplatin (100 mg/m², 3 doses)
Number of subjects: 109
Study 25263261 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 20
Study 25263261 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 20
Study 25263261 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivity
Number of subjects: 20
Study 25263261 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus CM
Number of subjects: 20
Study 25263261 — intervention group
Group type: COMPARATOR
Intervention: CM-control (non-contingent incentives)
Number of subjects: 20
Study 23393217 — intervention group
Group type: EXPERIMENTAL
Intervention: nurse-community health worker (CHW) team intervention
Number of subjects: 268